Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1142)	5/12/1998 3:32:00 PM
From: Rudy Saucillo	Read Replies (2) \| Respond to of 2742

There's really a substantial amount of research in the field. In the study below out of Duke, researchers show that IL-1b and IL-2 "act at least additively" in protecting mice against melanoma challenge. This work sounds to me to be somewhat complementary to the current work performed by Steven Rosenberg at NCI delivering IL-2 to melanoma tumors. Getting back to S. Harmon's comments, I don't understand why some "outsider" hasn't aggressively pursued the discounted dollars. Seems like the cash is there for the taking. Rudy Modulation of specific active immunization against murine melanoma using recombinant cytokines. Stidham KR, Ricci WM, Vervaert C, Abdel-Wahab Z, Seigler HF, Darrow TL Department of Surgery, Duke University Medical Centre, Durham, NC 27710, USA. Surg Oncol 1996 Oct;5(5-6):221-229 Specific active immunization with tumour cells and IL-1beta or IL-2 was examined in a murine model. Mice were treated with irradiated B16 melanoma, IL-1beta or IL-2 only, or with B16 plus cytokines prior to i.v. challenge with viable B16. Lung metastases were recorded after 28 days. Treatment with cytokine alone was not protective. Treatment with B16 alone afforded moderate protection. Treatment with B16 in combination with either cytokine resulted in a significant level of B16 specific protection which was dependent on the dose of cytokine used. Multiple immunizations with B16 provided limited protection which was significantly improved with IL-2. Immunization with B16 in combination with both cytokines at doses that alone failed to enhance immunity resulted in significant protection, suggesting that the two cytokines act at least additively. These studies demonstrate the significant benefit of specific active immunization with tumour cells in combination with low doses of IL-1beta or IL2.